

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SE
01 AUG 14 AM 9:

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Alpine Group, Inc.			
2. Registrant Address <input checked="" type="checkbox"/> Check if different than previously reported Address 660 Pennsylvania Avenue, SE Suite 201 City Washington State/Zip (or Country) DC 20003			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Monica Skopec		Telephone 202-548-2312	E-mail (optional) mskopec@alpinegroup.com
7. Client Name <input type="checkbox"/> Self DuPont Pharmaceuticals Company			5. Senate ID # 1171-90
			6. House ID # 31749006

TYPE OF REPORT 8. Year 2001 Midyear (January 1-June 30) OR Year End (July 1-De

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobby

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$40,000.00</u> Income (nearest \$20,000)	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of <input type="checkbox"/> Method A. Reporting amounts using LDA definiti <input type="checkbox"/> Method B. Reporting amounts under section 6033 the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(Internal Revenue Code

Signature *M Skopec* Date 07/30/2001

Printed Name and Title **Monica Skopec - Associate**
Filing #3dcf636e-26b5-4a58-86ed-4563a734cf6a - Page 1 of 4



Registrant Name: Alpine Group, Inc.

Client Name: DuPont Pharmaceuticals Company

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

General FDA issues relating to substitution of NTI drugs and patient notification of switching of NTI drugs.

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
White, Richard	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature

M. Skopec

Date

07/30/2001

Printed Name and Title

Monica Skopec - Associate

